Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infanrix-IPV/Hib Immunogenicity and Safety in Chinese Infants
NCT01086423Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2010
- Primary completion
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of diphtheria + tetanus + acellular pertussis + inactivated poliomyelitis + Haemophilus influenzae type b vaccine in diphtheria, Tetanus, pertussis and 2 more (3 arms), sponsored by GSK. Primary endpoints: Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Antigens, Number of Seroprotected Subjects Against Polyribosyl-ribitol-phosphate (PRP) Antigen and 2 more. Started Mar 2010; status: completed.
02
Drugs
diphtheria + tetanus + acellular pertussis + inactivated poliomyelitis + Haemophilus influenzae type b vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT01086423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01086423.